New User:

Forgot your password?

Stock Market & Financial Investment News

Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 17, 2015
10:03 EDTTITNTitan Machinery mentioned cautiously by TheStreetSweeper
Reference Link
10:01 EDTNKEUnder Armour, Nike slide after Dick's outlook misses expectations
Shares of Under Armour (UA) and Nike (NKE) slipped after Dick's Sporting Goods (DKS) provided guidance for the fourth quarter and fiscal 2015 that both missed consensus estimates. WHAT'S NEW: Dick's Sporting Goods reported Q3 adjusted earnings per share of 45c on revenue of $1.64B, mostly in-line with analyst estimates of 47c on revenues of $1.64B. The company guided for Q4 EPS of $1.10-$1.25, short of the consensus estimate of $1.43. Dick's also said it anticipates FY15 adjusted EPS of $2.85-$3.00, lower than current analyst expectations of $3.19. STREET RESEARCH: Following the report, Baird analyst Justin Kleber said that Dick's Sporting Goods is the "strongest player" in its segment, which should enable the company to grow its sector-leading 10% market share at the expense of smaller competitors. The analyst added that profitability for the company should improve as volumes increase and as the company leverages its store base to fulfill further orders. Kleber said that Dick's Sporting Goods' e-commerce business will be more profitable than its brick-and-mortar business by 2017. The analyst maintained a Neutral rating and $48 price target on Dick's Sporting Goods' stock. PRICE ACTION: In morning trading, Dick's Sporting Goods dropped 17.5% to $33.67, while supplier Under Armour fell 5.6% to $84.95 and Nike was down 2% to $121.08. Dick's peers fell as well, with Finish Line (FINL) dropping 1%, Foot Locker (FL) slid 1.3% and Cabela's (CAB) dipping marginally in morning trading.
08:05 EDTPANWPalo Alto volatility elevated into Q1 and outlook
Palo Alto November call option implied volatility is at 43, November weekly is at 69, December is at 54, January is at 46; compared to its 52-week range of 27 to 66, suggesting large near term price movement into the expected release of Q1 results on November 23.
07:47 EDTPSECWells Fargo to hold a forum
Subscribe for More Information
07:42 EDTPANWPalo Alto checks point to above-consensus Q1 results, says Stephens
Subscribe for More Information
07:37 EDTPANWPalo Alto results should beat expectations, says RBC Capital
Subscribe for More Information
07:27 EDTABCAmerisourceBergen reinstated with an Outperform at Credit Suisse
Subscribe for More Information
November 16, 2015
16:00 EDTTWTROptions Update; November 16, 2015
Subscribe for More Information
12:58 EDTTWTRStocks with call strike movement; VXX TWTR
Subscribe for More Information
12:53 EDTAKAMLimelight Networks responds to US Court of Appeals decision
Subscribe for More Information
10:00 EDTABCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alliant Energy (LNT) upgraded to Outperform from Market Perform at Wells Fargo... AmerisourceBergen (ABC) upgraded to Equal Weight from Underweight at Morgan Stanley... Amphenol (APH) upgraded to Buy from Neutral at Goldman... CA Technologies (CA) upgraded to Neutral from Sell at Citi... Cempra (CEMP) upgraded to Overweight from Equal Weight at Morgan Stanley... Edgewell Personal Care (EPC) upgraded to Neutral from Sell at Goldman... Eli Lilly (LLY) upgraded on improved growth outlook at BMO Capital... MiMedx (MDXG) upgraded to Strong Buy from Buy at Needham... NVIDIA (NVDA) upgraded to Buy from Hold at Canaccord... New York REIT (NYRT) upgraded to Buy from Hold at Evercore ISI... Oracle (ORCL) upgraded to Conviction Buy from Buy at Goldman... Perrigo (PRGO) upgraded to Buy from Neutral at UBS... Semtech (SMTC) upgraded to Buy from Neutral at B. Riley... Tullow Oil (TUWOY) upgraded to Buy from Neutral at UBS... Wabtec (WAB) upgraded to Outperform on valuatoin at Raymond James.
08:12 EDTALKSLeerink reiterates Outperform rating, $84 target on Alkermes
After hosting a conference call with CEO Richard Pops and CFO Jim Frates, Leerink analyst Paul Matteis reiterates an Outperform rating on Alkermes with an $84 price target. The analyst continues to believe the '5461 FORWARD Phase 3 program for depression is "employing a robust, proven study design." The drug likely only needs to hit on two of three pivotal efficacy studies for FDA approval, Matteis reiterates to investors in a research note.
08:06 EDTABCAmerisourceBergen upgraded to Equal Weight from Underweight at Morgan Stanley
Subscribe for More Information
07:57 EDTALKSLeerink biotech analyst holds an analyst/industry conference call
Biotech Analyst Matteis, along with MEDACorp specialists Anthony Rothschild, M.D., Director of the University of Massachusetts Depression Center and Darin Dougherty, M.D., Harvard Medical School, discuss their views on Alkermes' ALKS-5461's probability-of-success in Phase III and the commercial potential of ALKS-5461 on an Analyst/Industry conference call to be held on November 16 at 2 pm.
07:00 EDTBTBT shareholders warn that breakup would be destructive, Telegraph reports
Subscribe for More Information
06:32 EDTSWISolarWinds announces early termination of HSR waiting period
SolarWinds announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to its proposed acquisition by an affiliate of Silver Lake Partners and Thoma Bravo, was terminated early by the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice on November 12. As previously announced on October 21, SolarWinds has entered into a definitive agreement to be acquired by leading private equity technology investment firms Silver Lake and Thoma Bravo in a transaction valued at approximately $4.5B. Termination of the HSR Act waiting period is one of the specified conditions to which closing of the Merger is subject. The completion of the Merger remains subject to certain other closing conditions, including adoption of the Merger Agreement by our stockholders and the receipt of certain other non-United States regulatory approvals.
05:09 EDTNKEStocks with implied volatility movement; TJX NKE
Subscribe for More Information
November 13, 2015
09:39 EDTALKSLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
November 12, 2015
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
08:12 EDTTWTRDorsey addresses dual role concerns in Square private meetings, NYT says
In intimate meetings with select potential investors in Square's (SQ) IPO, Jack Dorsey addressed concerns about his dual CEO role, explaining that he splits time equally between Square and Twitter (TWTR) a few days a week and then allocates his remaining time based on need, according to the New York Times, citing a person who attended one of them. Dorsey also emphasized the power of his team, the person told the Times. Reference Link
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use